PROSCA/BLADDR 2023 | ProBio: a biomarker driven study in patients with metastatic prostate cancer

Bram De Laere, PhD, Ghent University in Belgium, discusses the ongoing Phase III ProBio (NCT03903835) trial, a liquid biopsy biomarker-driven platform trial for men with metastatic prostate cancer. The trial uses liquid biopsy screening to profile cell-tumor DNA (ctDNA) and select men with detectable ctDNA for randomization to different treatment arms. Dr De Laere shares preliminary data showing the feasibility of using liquid biopsy for treatment selection. The investigational arm with AR pathway inhibitors outperformed standard of care and taxane-based chemotherapy. Subsequent analysis revealed that men with wild-type TP53 derived the most significant benefit from pathway inhibitors, while those with TP53-altered disease had poorer outcomes, irrespective of treatment. The interaction analysis emphasized the predictive value of TP53 alterations, indicating the need for tailored treatment strategies for this subgroup. This interview took place at the Global Congress on Prostate and Bladder Cancer (PROSCA/BLADDR) 2023 in Malaga, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties worldwide. All rights are reserved.